ARCH PERSONAL CARE PRODUCTS AND GENELINK TO BEGIN MARKETING "GENETIC" SKIN CARE KIT AND FORMULATIONS TO MARKETERS AND MANUFACTURERS FOR THE PERSONAL CARE AND COSMETICS INDUSTRIES
February 11, 2003

MARGATE, NJ - BUSINESS WIRE - February 11, 2003 - GeneLink BioSciences, Inc. (OTCBB:GNLK) and Arch Personal Care Products, L.P., a unit of Arch Chemicals, Inc. (NYSE:ARJ) announced today that they intend to commence collaborative efforts to market newly developed formulations containing active skin care ingredients that can be linked to GeneLink's genetic testing system for determining an individual's skin characteristics. These new formulations will be offered to leading marketers and manufacturers for the personal care and cosmetic industries.

GeneLink and Arch Personal Care Products began collaborating on the development of a new category of "genetic" skin-care formulations and an associated, personalized skin-testing system in late 2001. Recently developed formulations feature a family of active ingredients known as "SNP-Derms" designed to address some of the key, individual genetic characteristics that can accelerate skin aging, skin wrinkling and other specific oxidative stress deficiencies in the skin. The SNP-DermÍ formulations may be offered in combination with GeneLink's Dermagenetic Profile AssessmentÍ that provides a measure of a person's resistance to skin aging, skin irritation and tissue breakdown.

"Arch Personal Care Products sees a significant future opportunity in customized, genetic profile-based cosmetics," says Andy Banham, Business Director. "We see the mapping of the human genome as a starting point for true customization of cosmetic and personal care products, and we're excited to be working closely with the company that we believe has pioneered a test that will allow this technology to be marketed to consumers in a meaningful way. We have worked for more than a year to develop new ingredients targeted at the specific stress weaknesses characterized by the genetic markers that can be identified by the GeneLink test. The SNP-DermÍ ingredients will be offered to cosmetic industry marketers and manufacturers as a means to accelerate their entrance into what appears to be a promising, newly emerging consumer market."

"The consumer increasingly wants cosmetics and personal care products as part of a precautionary health regimen," says John DePhillipo, GeneLink's CEO. "We are very pleased we could combine GeneLink's scientific resources with Arch Personal Care Products' expertise and can now offer this remarkable new technology to the manufacturers that will ultimately bring new cosmetic and personal care products to a ready marketplace."

Arch Personal Care Products, L.P., a business unit within the Treatment Products business segment of Arch Chemicals, Inc., sells active ingredients to both the skin and hair care segments of the cosmetic and toiletries industries. Additional information about the Arch Personal Care Business can be found at its Web site at www.archpersonalcare.com 

Headquartered in Norwalk, CT, Arch Chemicals is a global specialty chemicals company with approximately $1 billion in annual sales. Together with its subsidiaries and affiliates, Arch has more than 3,000 employees and manufacturing facilities in North America, South America, Europe, Asia and Africa. Arch and its subsidiaries have leadership positions in four key segments -- Microelectronic Materials, Treatment Products, Performance Products and Other Specialty Products -- and serve world leaders in these markets with forward-looking solutions to meet their chemical needs.

About GeneLink: www.genelink.info. GeneLink BioSciences, Inc., a pioneer DNA banking and hereditary genetic information service has developed a proprietary method for genetic assessments (patents pending) and has begun to license these breakthrough nutragenetic and dermagenetic profiles to companies that market or manufacture products for the $100 billion plus skin care, nutritional supplement and health care industries.

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.